DA-1726 is MetaVia's once-weekly subcutaneous oxyntomodulin analog functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for obesity and MASH. The molecule was acquired through MetaVia's predecessor relationship with Korean partner Dong-A ST and inherits the oxyntomodulin pharmacology — a naturally occurring peptide that activates both incretin and glucagon pathways at a balanced 3:1 GLP1R:GCGR ratio.
The 4-week Phase 1 MAD trial earlier in 2026 documented compelling weight loss with what MetaVia frames as best-in-class potential for glucose control (GLP-1R arm), waist reduction (GCGR arm), and tolerability profile. The 48 mg cohort late-breaking poster at EASL 2026 Day 1 (May 27 Barcelona) added safety, tolerability, pharmacokinetics, and exploratory noninvasive liver assessment data. The 16-week Phase 1 Part 3 titration study is designed to optimize higher-dose levels with full data expected Q4 2026. The MetaVia ADA 2026 late-breaking abstracts (announced May 18) cover the Phase 1 Part 3 higher-dose titration results, scheduled for poster presentation June 7 in New Orleans.
Stories here cover DA-1726 trial readouts, the broader MetaVia cardiometabolic pipeline including vanoglipel (DA-1241 GPR119 agonist), and the GLP-1/glucagon dual-agonist competitive landscape. See #metavia, #glp-1-glucagon, and #oxyntomodulin for adjacent threads.
MetaVia's higher-dose Phase 1 readout for DA-1726 at EASL 2026 produced specific efficacy numbers: the 48 mg cohort in obese but otherwise healthy adults achieved 9.1% mean body-weight reduction and a 9.8 cm waist-circumference reduction at Day 54, with exploratory FibroScan liver improvements and no serious adverse events. DA-1726 is a once-weekly subcutaneous oxyntomodulin analog acting as a 3:1 ratio GLP-1/glucagon dual receptor agonist for obesity and MASH. The 9.1% weight loss in roughly eight weeks is a fast trajectory for an early-phase obesity peptide and supports MetaVia's case heading into the 16-week Phase 1 Part 3 titration study reading out Q4 2026. The waist reduction (a glucagon-receptor-driven visceral-fat signal) and the FibroScan liver improvements position DA-1726 in the dual obesity-and-MASH lane alongside survodutide and pemvidutide. MetaVia's three ADA 2026 late-breaking abstracts (June 7 New Orleans) extend the DA-1726 and vanoglipel data sets.
MetaVia presented late-breaking Phase 1 data on DA-1726 at the EASL Congress 2026 today in Barcelona. The poster titled 'Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DA-1726, an Oxyntomodulin Analogue, in a Higher-Dose Phase 1 Cohort with Exploratory Noninvasive Liver Assessment' covers the 48 mg dose level. DA-1726 is a once-weekly subcutaneous oxyntomodulin analog functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for obesity and MASH. The 4-week Phase 1 MAD trial earlier in 2026 documented compelling weight loss with best-in-class potential glucose control (GLP-1R arm), waist reduction (GCGR arm), and tolerability profile. The current 16-week Phase 1 Part 3 titration study is designed to optimize higher-dose levels and tolerability with full data expected Q4 2026. The EASL poster extends the early-phase MASH biomarker package and supports the planned Phase 2 advancement.
EASL 2026 Day 1 in Barcelona delivered the most concentrated MASH-therapeutics data cycle of 2026. The peptide-mechanism cohort: Altimmune pemvidutide qFibrosis fibrosis regression (LBP-036), MetaVia DA-1726 48 mg Phase 1 noninvasive liver assessment, Novo Nordisk ESSENCE Japanese/menopausal subgroups. The non-peptide-mechanism cohort: Arrowhead ARO-INHBE RNAi (Activin E/ALK7 pathway), Galectin Therapeutics belapectin NAVIGATE (galectin-3 inhibitor), Sagimet Biosciences denifanstat + resmetirom combination (FASN inhibitor + Madrigal's Rezdiffra), Madrigal eight-poster Rezdiffra data drop on cardiovascular and portal hypertension markers. The combined cycle reframes MASH as a multi-mechanism battleground rather than a single-class indication — GLP-1/glucagon peptides compete against thyroid-hormone-receptor agonism, RNAi, galectin-3 inhibition, FASN inhibition, and emerging combinations. Thursday May 28 brings the Altimmune pemvidutide oral presentation at 17:00 CEST; Friday May 29 brings ASCO opening in Chicago to anchor the parallel peptide-oncology cycle.
MetaVia confirmed Monday May 18 that three late-breaking abstracts have been accepted at the ADA 2026 Scientific Sessions (June 5-8 New Orleans). DA-1726 is a once-weekly subcutaneous oxyntomodulin analog functioning as a GLP-1R/GCGR dual agonist for obesity and MASH; Phase 1 Part 3 higher-dose titration results will be presented, with full Phase 1 trial data expected in Q4 2026. Vanoglipel (DA-1241) is a first-in-class GPR119 agonist that promotes endogenous release of GLP-1, GIP, and PYY from the gut; the ADA poster covers synergistic preclinical effects in combination with resmetirom (Madrigal's MASH therapy) and with metformin for type 2 diabetes. The three-poster slate positions MetaVia as one of several mid-cap obesity-pipeline names with clinical data inflections clustered into the ADA + ASCO + EASD 2026 calendar.
MetaVia dosed the first patient in a higher-dose Phase 1 study of DA-1726, its GLP-1 and glucagon dual agonist for obesity treatment, marking continued advancement in next-gen weight loss drugs.